Current Issues of Pharmacy and Medical Sciences

The effect of hormone replacement therapy on the expression of the alkaline phosphatase gene (ALPL) ...

Curr Issues Pharm Med Sci., Vol. 27, No. 2, Pages 92-96

Mansur Rahnama1, Michal Lobacz1, Anna Szyszkowska1, Grzegorz Trybek2, Maryla Kozicka-Czupkallo1

1 Chair and Department of Oral Surgery, Medical University of Lublin, Karmelicka 7, 20-081 Lublin, Poland

2 Department of Oral Surgery, Pomeranian Medical University, al. Powstańców Wlkp. 72, 70-111 Szczecin, Poland


DOI: 10.2478/cipms-2014-0021

Abstract

The effect of hormone replacement therapy on the expression of the alkaline phosphatase gene (ALPL) within the mucosal epithelium of the cheek and in peripheral blood lymphocytes
 
In adult life, proper bone metabolism requires efficient regulation of bone formation and resorption processes. Bone turnover markers allow for assessing the rate of bone formation and resorption processes. In menopausal period, female patients experience gradual reduction in blood estradiol levels. The deficit of estrogens leads to enhanced osteoclastogenesis and bone resorption. Alkaline phosphatase (ALP) is a membrane-bound enzyme that stimulates the osteoblast activity and bone mineralization. It is synthesized by osteoblasts and incorporated into the newly formed bone tissue. The produced enzyme stimulates the osteoblast activity and bone mineralization. The goal of this study is to determine the effect of hormone replacement therapy in post-menopausal women on the expression of alkaline phosphatase gene (ALPL) within the mucosal epithelium of the cheek and in peripheral blood lymphocytes. The studies show that hormone replacement therapy has no significant effect on the increase in ALPL expression within the mucosal epithelium of the cheek. Only in women having undergone ovarectomy (OV), the epithelial ALPL expression level was higher than in the remaining groups.
 

Keywords

alkaline phosphatase, bone turnover markers, menopausal period, ovarectomy hormone replacement therapy

References

  1. Chomczynski P., Sacchi N.: Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-9, 1987.
  2. Edman C.D.: Przekwitanie (klimakterium) (1989). In: Menopauza. Red. Buchsbauni HJ. PZWL. Warsaw, p. 34-44.
  3. Gajewska J., Ambroszkiewicz J., Laskowska-Klita T.: Wybrane markery obrotu kostnego w surowicy krwi dzieci w zależności od wieku i płci; Wiad, Lek., 2005, 58, 9-10, 2005.
  4. Garnero P., Hauser E., Chapuy M.C. et al.: Markers of bone predict hip fractures in elderly women. J Bone Min Res 11, 1531–38, 1996.
  5. Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D.: Biochemicalmarkers of bone turnover, endogenous hormones and the risk offractures in postmenopausal women. J. Bone Miner. Res., 15, 1526-36, 2000.
  6. Garnero P.: Bone markers in osteoporosis. Curr. Osteoporos. Rep., 7, 84–90, 2009.
  7. Hansen M., Overgaard K., Riis B., Christiansen C.: Role of peak bonemass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ, 303, 961–64, 1991.
  8. Jurkowski P., Mierzwińska-Nastalska E., Kostrzewa-Janicka J.: Use of Biochemical Markers of Bone Turnover in General Medicine and Dentistry. Dent. Med. Probl., 47, 2, 199-205, 2010
  9. Karczmarewicz E.: Markery obrotu kostnego. Nieinwazyjna ocena parametrów jakości kości. Osteoforum 2008
  10. Karczmarewicz E.: Wartość diagnostyczna markerów obrotu kostnego. Osteoforum 2006.
  11. Kraenzlin M.E.: Biochemical Markers of Bone Turnover and Osteoporosis Management. BoneKEy, 4, 191–203, 2007.
  12. Lerner U.H.: Bone remodeling in post-menopausal osteoporosis. J. Dent. Res., 85, 584-595, 2006.
  13. Marcinowska-Suchowierska (1999): Osteoporoza - diagnostyka, profilaktyka i leczenie. PZWL. Warszawa.
  14. Nawawi H.M. et al.: Serum bone specific alkaline phosphatase and urinary deoxypyridinoline in postmenopausal osteoporosis. Malays J Pathol., 23, 79-88, 2001.
  15. Naylor K.E., Eastell R.: Measurement of biochemical markers of bone formation. In:Seibel M, Robins S, Bilezikian J, eds. Dynamics of bone and cartilage metabolism. Academic Press, 529–40, 2006.
  16. Rachoń D., Myśliwska J., Suchocka-Rachoń K.: Wpływ przezskórnej estrogenoterapii na produkcję interleukiny-6 u kobiet w wieku pomenopauzalnym. Przegl. Menopauz., 2, 22-27, 2002.
  17. Rahnama M. et al.: Wpływ stosowania hormonoterapii zastępczej na stężenie fosfatazy zasadowej i fosfatazy kwaśnej w surowicy i ślinie u kobiet z niedoborem estrogenów. Przegl. Menopauz., 6, 506–9, 2012.
  18. Schiele F. et al.: Total bone and liver alkaline phosphatases in plasma: biological variations and reference limits. Clin Chem., 29, 634-41, 1983.
  19. Takahashi M. et al.: Comparison of bone and total alkaline phosphatase activity on bone turnover during menopause and in patients with established osteoporosis. Clin. Endocrinol. (Oxf), 47, 177-83, 1997.
  20. Warenik-Szymankiewicz A., Stopień R.: Zastosowanie niskich dawek estrogenów jako nowej strategii w osteoporozie pomenopauzalnej. Terapia, 9, 11, 19-22, 2001.
  21. Warenik-Szymankiewicz A.: Hormonalna terapia zastępcza w okresie okołomenopauzalnym. Terapia, 5, 3-14, 1997.
  22. Weitzmann M., Pacifici R.: Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest., 116, 1186–94, 2006.
  23. Zgliczyński S.: Globalizacja w osteoporozie. JAMA PL, 5(1-2), 75-6, 2003.

Calendar

April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30